Gruthan Bioscience receives funding to develop a novel class of cholesterol-lowering drugs

(Medical University of South Carolina) Medical University of South Carolina startup Gruthan Bioscience has been awarded National Institutes of Health funding to develop novel drugs to treat a rare and deadly form of familial hypercholesterolemia. Patients with this disease do not respond to current cholesterol-lowering drugs on the market, so new therapeutics are urgently needed. Gruthan Bioscience founder Stephen Duncan, Ph.D., hopes this novel class of cholesterol-lowering drugs can also be us...